KR20180076607A - Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same - Google Patents
Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same Download PDFInfo
- Publication number
- KR20180076607A KR20180076607A KR1020160180951A KR20160180951A KR20180076607A KR 20180076607 A KR20180076607 A KR 20180076607A KR 1020160180951 A KR1020160180951 A KR 1020160180951A KR 20160180951 A KR20160180951 A KR 20160180951A KR 20180076607 A KR20180076607 A KR 20180076607A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- water
- cosmetic composition
- sleep
- melatonin
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 115
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- 241000631640 Ishige okamurae Species 0.000 title claims abstract description 11
- 230000006698 induction Effects 0.000 title description 17
- 230000014509 gene expression Effects 0.000 claims abstract description 34
- 230000001939 inductive effect Effects 0.000 claims abstract description 34
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960003987 melatonin Drugs 0.000 claims abstract description 33
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 229940008099 dimethicone Drugs 0.000 claims description 26
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 26
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 26
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 12
- 229920006037 cross link polymer Polymers 0.000 claims description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 10
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 9
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 9
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- 229960000281 trometamol Drugs 0.000 claims description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 9
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- -1 cetearyl olivate Chemical compound 0.000 claims description 8
- 235000020221 chamomile extract Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- LVQSCKUKDKAQGO-UHFFFAOYSA-L disodium;diiodide Chemical compound [Na+].[Na+].[I-].[I-] LVQSCKUKDKAQGO-UHFFFAOYSA-L 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 6
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001593 sorbitan monooleate Substances 0.000 claims description 6
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 6
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229940119217 chamomile extract Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- 235000020723 lavender extract Nutrition 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- 240000005717 Dioscorea alata Species 0.000 claims description 3
- 240000008415 Lactuca sativa Species 0.000 claims description 3
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 208000007542 Paresis Diseases 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229940083980 lavender extract Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 3
- 208000012318 pareses Diseases 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229940057874 phenyl trimethicone Drugs 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 3
- 235000008160 pyridoxine Nutrition 0.000 claims description 3
- 239000011677 pyridoxine Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 3
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 3
- 229940080313 sodium starch Drugs 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 235000020238 sunflower seed Nutrition 0.000 claims description 3
- 229940092665 tea leaf extract Drugs 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- FVKRIDSRWFEQME-UHFFFAOYSA-N 3-methylbutyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCC(C)C FVKRIDSRWFEQME-UHFFFAOYSA-N 0.000 claims description 2
- 240000003291 Armoracia rusticana Species 0.000 claims description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940078565 isoamyl laurate Drugs 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 239000003760 tallow Substances 0.000 claims description 2
- 102000001419 Melatonin receptor Human genes 0.000 abstract description 36
- 108050009605 Melatonin receptor Proteins 0.000 abstract description 36
- 235000013305 food Nutrition 0.000 abstract description 8
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 241000631636 Ishige Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- IKEDSFDUOMJWHK-UHFFFAOYSA-L disodium hydroxy-oxido-sulfanylidene-sulfido-lambda5-phosphane Chemical compound P(=S)([S-])([O-])O.[Na+].[Na+] IKEDSFDUOMJWHK-UHFFFAOYSA-L 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GUBGYTABKSRVRQ-XAQNGTHUSA-N (2S,3S,4R,5S,6R)-2-(hydroxymethyl)-6-[(2S,3R,4S,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@H]1[C@H](CO)OC(O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-XAQNGTHUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MTFFANYLEXKMTD-UHFFFAOYSA-N 1-hydroxy-1-phenylurea Chemical compound NC(=O)N(O)C1=CC=CC=C1 MTFFANYLEXKMTD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000208822 Lactuca Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000021907 regulation of circadian rhythm Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 패(Ishige okamurae) 추출물을 유효성분으로 포함하는 수면유도 기능성 조성물에 관한 것으로, 더욱 상세하게는 해조류 중 한 가지인 패(Ishige okamurae)의 추출물이 멜라토닌 및 멜라토닌 수용체(MT1)의 발현을 증가시켜 수면을 유도하는 효능이 있음을 최초로 확인하고, 이러한 패 추출물을 수면유도용 기능성 화장료 조성물, 식품 조성물 또는 약제학적 조성물의 유효성분으로 사용한 용도에 관한 것이다.The present invention is based on the idea that Ishige okamurae) relates to a sleep inducing functional composition comprising the extract as an active ingredient, and more particularly, to a hand one of the seaweed (Ishige okamurae extract of the present invention has an effect of inducing sleeping by increasing the expression of melatonin and melatonin receptor (MT1), and it has been confirmed that these extracts can be used as an effective ingredient of a functional cosmetic composition for food, a food composition or a pharmaceutical composition And the use thereof.
사회가 급속도로 발전함에 따라 많은 스트레스와 불안감을 유발시킬 수 있는 요소들이 증가하고 있으며, 수면장애 현상을 겪고 있는 사람의 수가 늘고 있다. 더욱이 인구의 노령화에 따른 불면증 및 신경불안증 등의 질병이 증가하고 있는 현실에서, 이를 치료 및 예방할 수 있는 부작용이 적은 약재 내지 보조제품에 대한 개발이 절실히 요구되고 있다.As society develops rapidly, there are increasing factors that can cause a lot of stress and anxiety, and the number of people suffering from sleep disorders is increasing. Furthermore, in the reality that diseases such as insomnia and nervous anxiety due to the aging of the population are increasing, it is urgently required to develop medicines or ancillary products with less side effects that can be treated and prevented.
수면유도를 포함한 일주기 조절에 있어서는 멜라토닌(melatonin)이라는 호르몬의 증감 현상이 대표적인 조절 메커니즘으로 알려져 있다. 구체적으로 증가된 멜라토닌은 세포벽의 멜라토닌 수용체(MT1, MT2)에 의해 세포내로 수면유도 명령 신호를 전달하는 형식으로 수면유도 현상이 조절된다.Melatonin is known to be a major regulatory mechanism in the regulation of circadian rhythm including sleep induction. Specifically, increased melatonin is mediated by the melatonin receptors (MT1, MT2) on the cell walls, which regulate sleep induction in a way that signals sleep induction.
따라서, 수면조절을 위한 소재 및 약재의 개발과 관련하여, 체내 멜라토닌 함량 및 멜라토닌 수용체가 수면유도 현상을 포함한 일주기를 조절하기 위한 중요한 타겟분자로 작용할 수 있다.Therefore, in relation to the development of materials and medicines for controlling sleep, the contents of melatonin in the body and the melatonin receptors may act as important target molecules for controlling the circadian cycle including the induction of sleep.
패(Ishige okamurae)는 국내 남부해안 각지 및 제주도 연안 등에 분포하는 해양식물성 갈조류로서, 그 효능을 탐구하려는 연구들이 일부 진행된 바 있다. Ishige Okamurae ) is a marine vegetable brown algae distributed in the southern coast of Korea and Jejudo coast. Some studies have been conducted to investigate its efficacy.
예를 들어, 한국등록특허 제10-0981184호는 패 추출물에 항산화 활성이 있다고 기재하면서 이를 유효성분으로 이용한 천연 항산화제에 대해 개시하고 있다.Korean Patent No. 10-0981184, for example, discloses that Lactobacillus root extract has an antioxidative activity and discloses a natural antioxidant using it as an active ingredient.
그러나, 아직까지 패(Ishige okamurae)의 다른 다양한 효능들에 대한 연구는 미진한 상태이며, 특히 패 추출물에 수면유도 내지 숙면유도 효능이 있음을 밝힌 연구는 전무하다.However, still it lost (Ishige up Studies on other diverse efficacies of okamurae have been limited , and there have been no studies that have shown that Lepidoptera induces sleep induction or sleep induction.
본 발명은 상기와 같은 종래의 요구를 충족시키기 위한 것으로, 본 발명자들은 해양 천연소재인 패(Ishige okamurae)를 이용하여 수면유도 효능을 보유한 소재를 개발하기 위해 예의 연구를 거듭하였으며, 패 추출물 처리에 따른 수면유도 물질(melatonin)의 유도 여부 및 멜라토닌 수용체 발현의 변화를 구체적으로 검증하여 패 추출물의 수면유도 효능 보유 여부를 구체적으로 확인하고, 본 발명에 이르렀다.DISCLOSURE OF THE INVENTION The present invention has been made to solve the above-mentioned conventional needs, The results showed that the induction of melatonin and the changes of melatonin receptor expression in the treatment of Lappa extract resulted in a significant increase in sleep Inducing activity, and reached the present invention.
즉, 본 발명은 수면유도 기능을 가지는 패 추출물을 포함하는 기능성 조성물, 특히 화장료 조성물을 제공하는 것을 기술적 과제로 한다.That is, a technical object of the present invention is to provide a functional composition, particularly a cosmetic composition, comprising a Lactuca extract having a water-inducing function.
상기한 기술적 과제를 달성하고자, 본 발명은 패(Ishige okamurae) 추출물을 유효성분으로 포함하는 수면유도 기능성 조성물을 제공한다.To achieve the above-mentioned technical problem, the present invention provides the L (Ishige The present invention provides a water- insoluble functional composition comprising an extract of Okamurae as an active ingredient.
본 발명은 해양 갈조류의 한 가지인 패(Ishige okamurae)의 추출물에 수면유도 효능이 존재함을 최초로 발견한 것으로서, 세포수준(in vitro) 및 동물(in vivo) 실험 결과 수면유도에 중요한 역할을 하는 멜라토닌(melatonin) 호르몬이 4주간의 패 추출물을 급여한 마우스의 혈청에서 증가함과 더불어, 패 추출물을 뇌세포(glioma cell)에 처리를 하였을 경우 멜라토닌 수용체(melatonin receptor 1; MT1)의 발현이 증가하는 것을 확인하였으며, 4주간의 패 추출물을 급여한 마우스의 뇌에서도 대조군에 비해 멜라토닌 수용체(MT1)가 증가하는 것을 확인하였다.The invention marine brown algae one kinds of L (Ishige of as an extract sleep induction effect first found that the presence in the okamurae), the cellular level (in vitro) and animal (in vivo) experiments melatonin (melatonin) hormones for 4 weeks L extract that play an important role in sleep induction The increase in melatonin receptor (MT1) expression was observed in the serum of the fed mice and when the extract was administered to brain cells (glioma cells), the expression of melatonin receptor 1 (MT1) Melatonin receptor (MT1) increased in the brain of one mouse compared to the control group.
즉, 본 발명에 사용된 패 추출물은 수면유도에 직접적인 관련이 있는 멜라토닌 호르몬의 증가뿐만 아니라, 멜라토닌에 의한 세포내 신호전달(수면유도 신호전달) 기능을 담당하고 있는 멜라토닌 수용체를 증가시키는 것에 의해 뛰어난 수면유도 효능을 나타내는 것으로 파악되었다.In other words, the Lard extract used in the present invention is excellent in not only the increase of melatonin hormone directly related to the induction of sleep but also the increase of the melatonin receptor which is responsible for the intracellular signal transduction (sleep surface induction signal transduction) function by melatonin And it was found that it exhibited sleep inducing efficacy.
구체적으로, 본 발명에서 사용하는 패 추출물은 DPHC(diphloroethohydroxycarmalol) 성분을 10% 이상 함유하는데(하기 표 1 참조), 이 성분이 수면 유도효과를 유발하는 것으로 여겨진다.Specifically, the Lahmang extract used in the present invention contains more than 10% of DPHC (diphloroethohydroxycarmalol) component (see Table 1 below), and this component is considered to cause a sleep inducing effect.
[표 1][Table 1]
본 발명에 있어서, 패 추출물을 얻는 방법은 특별히 제한되지 않으며, 천연 소재로부터 유효성분을 추출해내는 당분야의 통상적인 방법에 의해 패 추출물을 수득할 수 있다.In the present invention, there is no particular limitation on the method for obtaining the Lactobacillus root extract, and the Lactobacillus root extract can be obtained by a conventional method in the field of extracting the active ingredient from natural materials.
예를 들어, 제주 연안 등에서 직접 채취한 패를 세척, 건조(예컨대, 동결건조) 및 분쇄하여 분말화한 후, 건조 중량의 약 2~20배(예컨대, 약 10배)에 달하는 부피의 물, 메탄올, 에탄올 및 부탄올과 같은 저급알콜 중에서 선택된 용매(예컨대, 물)로 20~100℃(예컨대, 70℃)의 추출온도에서 약 0.5시간~2일(예컨대, 1시간~1일) 동안 열수 추출, 냉침 추출, 환류냉각 추출 또는 초음파 추출 등의 방법(예컨대, 열수 추출)으로 추출한 뒤, 필요시 잔사제거, 여과 및 농축 과정을 추가하여 본 발명의 패 추출물을 준비할 수 있다. 또한 농축하여 얻은 추출물을 물에 용해시킨 후, 에틸아세테이트 등으로 분획을 실시하고, 에틸아세테이트 층을 감압건조하여 분획물을 수득할 수 있다. 또한 농축하여 얻은 추출물을 동결건조하여 분말화된 상태로 준비할 수 있다.For example, the pellets collected directly from the coast of Jeju and the like are washed, dried (e.g., lyophilized) and pulverized and pulverized, and then washed with water having a volume of about 2 to 20 times (for example, about 10 times) (For example, 1 hour to 1 day) at an extraction temperature of 20 to 100 ° C (for example, 70 ° C) with a solvent selected from among lower alcohols such as methanol, ethanol and butanol , Extraction with cold extraction, reflux cooling extraction or ultrasonic extraction (for example, hot water extraction), and then, if necessary, residue removal, filtration and concentration are added to prepare the extract of the present invention. Further, the extract obtained by concentration is dissolved in water, followed by fractionation with ethyl acetate or the like, and the ethyl acetate layer is dried under reduced pressure to obtain a fraction. The concentrated extract can be lyophilized and prepared in a powdered state.
특히, 본 발명은 패(Ishige okamurae) 추출물을 유효성분으로 포함하는 수면유도 기능성 화장료 조성물(화장품류)을 제공한다.In particular, the present invention provides the L (Ishige (cosmetics) comprising an extract of Okamurae as an active ingredient.
본 발명에 따르면, 불면증 및 신경불안증을 해소할 수 있는 새로운 기능성 화장품을 제조할 수 있으며, 예를 들어 본 발명의 수면유도 기능성 화장품을 잠자기 전에 바르고 자면 숙면을 취할 수 있다.According to the present invention, new functional cosmetics capable of eliminating insomnia and nervous anxiety can be manufactured. For example, the sleep-inducing functional cosmetic of the present invention can be put to sleep before sleeping.
구체적으로, 본 발명은 패 추출물이 함유된 하기와 같은 4종의 화장품류를 개발하였으며, 이러한 제품들은 임상실험을 통해 수면유도 효과가 있는 것으로 판명되었다.Specifically, the present invention has developed four kinds of cosmetics such as the following ones containing a Lard extract, and these products have proven to have a sleep inducing effect through clinical experiments.
제 1예로, 본 발명의 수면유도 기능성 화장료 조성물은 에센스 타입이며, 정제수, 사이클로펜타실록산, 부틸렌글라이콜, 글리세린, 바이오사카라이드검-1, 디메치콘, 마치현추출물, 1,2-헥산디올, 피이지-10디메치콘/비닐디메치콘크로스폴리머, 폴리소르베이트20, 하이드록시아세토페논, 디메치콘/비닐디메치콘크로스폴리머, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 트로메타민, 카보머, 패 추출물, 토코페릴아세테이트, 알란토인, 소듐하이알루로네이트, 디메치콘올, 디소듐이디티에이 및 향료를 포함하는 것이다.As a first example, the water-surface-inducing functional cosmetic composition of the present invention is an essence type and is an essence type, and it is an essence type, and it is an essence type, such as purified water, cyclopentasiloxane, butyleneglycol, glycerin, biosaccharide gum-1, dimethicone, 10 dimethicone / vinyl dimethicone crosspolymer,
본 제형의 경우, 우수한 수면유도 기능 외에, 패 추출물이 피부탄력을 강화시켜 주고, 마치현 추출물을 함유하여 외부환경으로 인해 민감해진 피부를 촉촉히 달래주며, 알란토인 성분을 함유하여 트고 거칠어진 피부의 개선 및 피부 장벽을 강화시켜 주는 효과가 있다.In addition to its excellent water-inducing function, this formulation enhances skin elasticity, moisturizes the skin sensitive to external influences, contains allantoic components, and improves the rough and rough skin. It has the effect of strengthening skin barrier.
제 2예로, 본 발명의 수면유도 기능성 화장료 조성물은 크림 타입이며, 정제수, 세틸에칠헥사노에이트, 글리세린, 부틸렌글라이콜, 1,2-헥산디올, 하이드로제네이티드폴리(C6-14올레핀), 이소아밀라우레이트, 세테아릴올리베이트, 소르비탄올리베이트, 마치현추출물, 글리세릴스테아레이트, 하이드록시아세토페논, 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머, 트로메타민, 캐모마일추출물, 국화꽃추출물, 디메치콘, 마테잎추출물, 상추추출물, 라벤더추출물, 패 추출물, 토코페릴아세테이트, 잔탄검, 소듐하이알루로네이트, 참마뿌리추출물, 하이드롤라이즈드옥수수전분, 베타-글루칸, 슈크로오스, 디소듐이디티에이 및 향료를 포함하는 것이다.As a second example, the water-surface-inducing functional cosmetic composition of the present invention is a cream-type composition and contains purified water, cetyl ethylhexanoate, glycerin, butylene glycol, 1,2-hexanediol, hydrogencarbonate poly (C6-14 olefin) , Cholesterol stearate, hydroxyacetophenone, acrylate / C10-30 alkyl acrylate crosspolymer, tromethamine, chamomile extract, chrysanthemum extract Extracts of flowers, flower extracts, dimethicone, matte extract, lettuce extract, lavender extract, Lard extract, tocopheryl acetate, xanthan gum, sodium hyaluronate, yam root extract, hydrolyzed corn starch, beta-glucan, sucrose , Disodium iodide, and fragrances.
본 제형의 경우, 우수한 수면유도 기능 외에, 패 추출물이 피부탄력을 강화시켜 주고, 라벤더 및 캐모마일 추출물을 함유하여 잠자는 동안 피부건조 예방, 피부 진정 및 자극을 완화시켜 주며, 참마의 점액질 성분인 무틴과 사포닌, 알란토인 등을 함유하여 피부 보호 및 천연 보습막 형성에 의해 피부를 촉촉하고 매끄럽게 유지해 주는 효과가 있다.In addition to its excellent sleep inducing function, this extract enhances skin elasticity, and contains lavender and chamomile extracts to prevent skin dryness during sleep, alleviate skin sedation and irritation, It contains saponin and allantoin to keep skin moist and smooth by protecting skin and forming natural moisturizing film.
제 3예로, 본 발명의 수면유도 기능성 화장료 조성물은 올인원 크림 타입이며, 정제수, 글리세린, 하이드록시에칠우레아, 나이아신아마이드, 프로판디올, 스쿠알란, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 피이지/피피지-17/6코폴리머, 부틸렌글라이콜, 디메치콘, 페닐트리메치콘, 트리에칠헥사노인, 디메치콘/비닐디메치콘크로스폴리머, 첨차잎추출물, 카프릴릴글라이콜, 패 추출물, 토코페릴아세테이트, 소듐하이알루로네이트, 카프릴하이드록사믹애씨드, 해바라기씨오일, 아데노신, 비에이치티, 아가, 카라기난추출물, 콩오일, 소듐스타치옥테닐석시네이트, 말토덱스트린, 칼슘판토테네이트, 소듐아스코빌포스페이트, 피리독신에이치씨엘, 빅사씨오일, 토코페롤, 실리카, C12-14파레스-12, 디소듐이디티에이, 페녹시에탄올 및 클로페네신을 포함하는 것이다.As a third example, the water-surface-inducing functional cosmetic composition of the present invention is an all-in-one cream type, and can be used in various forms such as purified water, glycerin, hydroxyphenylurea, niacinamide, propanediol, squalane, ammonium acryloylmethyltaurate / / FFP-17/6 copolymer, butyleneglycol, dimethicone, phenyltrimethicone, triethyhexanone, dimethicone / vinyl dimethicone crosspolymer, succulent tea leaf extract, caprylic glycol, , Tocopheryl acetate, sodium hyaluronate, caprylic hydroxamic acid, sunflower seed oil, adenosine, Baiichi tea, agar, carrageenan extract, soybean oil, sodium starch octenyl succinate, maltodextrin, calcium pantothenate , Sodium ascorbyl phosphate, pyridoxine HCSEEL, Vicassian oil, tocopherol, silica, C12-14 pares-12, disodium iodide, phenoxyethanol and clophenethine It will be included.
본 제형의 경우, 우수한 수면유도 기능 외에, 오일베이스와 워터베이스가 적절히 블렌딩되어 있어 밀리지 않는 산뜻하고 가벼운 사용감으로 히아루론산과 글리세린이 빠르게 피부에 흡수되어 충분한 수분을 공급해 주고, 스쿠알란과 비타민E를 함유하여 순하게 피부를 보호 및 영양감을 주어 피부에 촉촉한 윤기를 더해 매끄러운 피부로 가 꾸어 주며, 첨차추출물을 함유하여 피부 진정, 보습력 증가 및 지친 피부에 활력을 주는 효과가 있다.In addition to its excellent water-inducing function, this product is blended with an oil base and a water base, so that it is fresh and light, so that hyaluronic acid and glycerin are quickly absorbed into the skin to provide a sufficient amount of water. It contains squalane and vitamin E Protects and protects the skin and gives it a nutritive sensation. It gives a moisturizing shine to the skin and gives it a smooth skin. It contains a citrus extract to calm the skin, increase the moisturizing power and revitalize the weary skin.
제 4예로, 본 발명의 수면유도 기능성 화장료 조성물은 토너(토닝워터) 타입이며, 정제수, 에탄올, 부틸렌글라이콜, 나이아신아마이드, 1,2-헥산디올, 글리세레스-26, 마치현추출물, 하이드록시아세토페논, 피이지-40하이드로제네이티드캐스터오일, 옥틸도데세스-16, 패 추출물, 판테놀, 라벤더추출물, 상추추출물, 마테잎추출물, 하이드록시에칠셀룰로오스, 국화꽃추출물, 캐모마일추출물, 카보머, 트로메타민, 소듐하이알루로네이트, 디소듐이디티에이, 클로페네신 및 향료를 포함하는 것이다.In a fourth aspect, the present invention relates to a water-insoluble functional cosmetic composition which is toner (toning water) type and contains purified water, ethanol, butyleneglycol, niacinamide, 1,2-hexanediol, glycereth- Extracts of chrysanthemum flowers, chamomile extracts, carbomes, extracts of chrysanthemum extract, chrysanthemum extract, chrysanthemum extract, chrysanthemum extract, Tromethamine, sodium hyaluronate, disodium iodide, clofenesin and fragrances.
본 제형의 경우, 우수한 수면유도 기능 외에, 패 추출물이 피부탄력을 강화시켜 주고, 라벤더 및 캐모마일 추출물을 함유하여 피부주기의 순환을 활성화시켜 새로운 피부층으로의 전환을 돕고 예민하고 민감해져 있는 피부에 편안한 진정을 부여하여, 마치현추출물을 함유하여 피부건조 예방 및 뛰어난 보습력으로 잠자는 동안 피부를 진정시키고 자극을 줄여주는 효과가 있다.In addition to its excellent water-inducing properties, this extract enhances skin elasticity, contains lavender and chamomile extracts to help revitalize the cycle of the skin cycle, helping to transform into a new skin layer, To prevent dryness of the skin and excellent moisturizing power, so as to calm the skin while sleeping and to reduce irritation.
상기 4종의 수면유도 기능성 화장료 조성물에서, 유효성분인 패 추출물은 0.1~10 중량%(예컨대, 2 중량%), 정제수는 40~70 중량%(예컨대, 50 중량%), 기타 성분들은 합계 20~50 중량%(예컨대, 각각 동량으로 합계 48 중량%)의 수준으로 포함될 수 있으나, 반드시 이에 한정되는 것은 아니다.In the four types of water-induced functional cosmetic compositions, 0.1 to 10% by weight (for example, 2% by weight) of the extract of L-Lactose as an active ingredient, 40 to 70% by weight (for example, 50% by weight) of purified water, To 50% by weight (e.g., equal to 48% by weight in total, respectively), but are not limited thereto.
한편, 본 발명은 수면유도 기능이 필요한 식품 및 의약품의 소재로도 적용될 수 있다. 따라서 본 발명의 다른 측면으로 패(Ishige okamurae) 추출물을 유효성분으로 포함하는 수면유도 기능성 식품 조성물 및 수면유도 기능성 약제학적 조성물이 제공된다.In addition, the present invention can be applied to foods and medicines that require a sleep-inducing function. Thus a further aspect of the present invention L (Ishige a water-induced functional food composition and a water-induced functional pharmaceutical composition comprising an extract of Okamurae as an active ingredient.
본 발명의 유효성분인 패 추출물이 첨가되는 상기 식품의 종류에는 특별한 제한이 없으며, 예를 들어 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food to which the extract of the present invention is added. For example, it includes all kinds of health foods in the ordinary sense such as drinks, tea, drink, alcoholic beverage and vitamin complex.
상기 식품은 유효성분인 패 추출물 외에, 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 상기 식품은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있으며, 이러한 성분은 독립적으로 또는 혼합되어 사용될 수 있다.The food may contain various ingredients such as various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the food may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks, and these ingredients may be used independently or in combination.
또한, 본 발명의 약제학적 조성물은 약제학적으로 허용 가능한 첨가제를 추가적으로 포함할 수 있다. 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화분녹말, 옥수수전분, 분말셀룰로오스, 하이드록시프로필셀룰로오스, 전분글리콜산나트륨, 카르나우바납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨 및 탈크 등이 사용될 수 있으나, 반드시 이에 한정되는 것은 아니다. 이러한 첨가제는 약제학적 조성물 100 중량부에 대해 1~50 중량부 정도 포함될 수 있다.In addition, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive. Examples of pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogenphosphate, lactose, mannitol, sugar, arabic gum, cornstarch starch, powdered cellulose, But are not limited to, hydroxypropylcellulose, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol and talc. Such an additive may be included in an amount of 1 to 50 parts by weight based on 100 parts by weight of the pharmaceutical composition.
본 발명의 수면유도 기능성 식품 조성물 및 수면유도 기능성 약제학적 조성물은 유효성분인 패 추출물을 조성물 총 중량에 대하여 0.1~90 중량%의 함량으로 포함할 수 있다.The water-insoluble functional food composition and the water-surface-inducing functional pharmaceutical composition of the present invention may contain the extract of the present invention as an active ingredient in an amount of 0.1 to 90% by weight based on the total weight of the composition.
본 발명에 따른 수면유도 기능성 조성물은 멜라토닌뿐만 아니라 멜라토닌 수용체(MT1)의 발현을 증가시켜 우수한 수면유도 효능을 발휘한다.The sleep-inducing functional composition according to the present invention increases the expression of melatonin as well as the melatonin receptor (MT1), thereby exerting an excellent sleep-inducing effect.
특히, 본 발명의 수면유도 기능성 조성물은 불면증 및 신경불안증을 해소할 수 있는 기능성 화장품의 소재로 매우 적합하게 사용될 수 있으며, 기능성 식품 및 의약품의 소재로도 활용이 가능하다.In particular, the water-insoluble functional composition of the present invention can be suitably used as a material for functional cosmetics capable of solving insomnia and anxiety, and can also be used as a material for functional foods and medicines.
도 1은 패 추출물이 세포 생존율에 미치는 영향을 보여주는 그래프이다.
도 2는 패 추출물 처리에 의한 멜라토닌 수용체의 발현 변화를 보여주는 도면이다.
도 3은 패 추출물 급여에 따른 마우스의 체중 변화를 보여주는 그래프이다.
도 4는 패 추출물 급여에 따른 마우스의 멜라토닌 함량 변화를 보여주는 그래프이다.
도 5는 패 추출물 급여에 따른 마우스의 brain 멜라토닌 수용체 변화를 보여주는 도면이다.FIG. 1 is a graph showing the effect of Lard extract on cell viability.
Fig. 2 is a graph showing changes in expression of melatonin receptors by treatment with Lard extract.
FIG. 3 is a graph showing changes in body weight of a mouse according to the feeding of Lactobacillus extract.
FIG. 4 is a graph showing changes in the content of melatonin in mice according to the feeding of Lactobacillus extract.
FIG. 5 is a graph showing changes in brain melatonin receptors in mouse according to the feeding of Lactobacillus extract.
이하, 실시예 및 실험예를 통해 본 발명을 보다 구체적으로 설명한다. 그러나 하기 예는 본 발명의 이해를 돕기 위한 것일 뿐 어떠한 의미로든 본 발명의 범위가 이들 예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. It is to be understood, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
실시예Example
(1) (One) 제조예Manufacturing example
제주 연안 등 자연에서 직접 채취한 패를 세척, 동결건조 및 분쇄하여 분말화한 후, 건조 중량의 약 10배에 달하는 부피의 물로 70℃에서 1시간~1일(예컨대, 3시간) 동안 열수 추출한 다음, 잔사를 제거한 후 농축하고 필요시 동결건조 및 분말화하여 실시예에 사용할 패 추출물을 준비하였다.The tiles collected directly from nature such as the coast of Jeju are washed, lyophilized and pulverized and powdered, and then subjected to hot extraction at 70 ° C for 1 hour to 1 day (for example, 3 hours) in water having a volume of about 10 times the dry weight Next, the residue was removed and concentrated. If necessary, the extract was lyophilized and pulverized to prepare Lard extract to be used in the examples.
(2) (2) 실시예Example 1 One
정제수, 사이클로펜타실록산, 부틸렌글라이콜, 글리세린, 바이오사카라이드검-1, 디메치콘, 마치현추출물, 1,2-헥산디올, 피이지-10디메치콘/비닐디메치콘크로스폴리머, 폴리소르베이트20, 하이드록시아세토페논, 디메치콘/비닐디메치콘크로스폴리머, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 트로메타민, 카보머, 패 추출물, 토코페릴아세테이트, 알란토인, 소듐하이알루로네이트, 디메치콘올, 디소듐이디티에이 및 향료를 균일하게 배합하여 에센스 타입의 화장품을 제조하였다.1, dimethicone, horseradish extract, 1,2-hexanediol, phage-10 dimethicone / vinyl dimethicone crosspolymer,
(3) (3) 실시예Example 2 2
정제수, 세틸에칠헥사노에이트, 글리세린, 부틸렌글라이콜, 1,2-헥산디올, 하이드로제네이티드폴리(C6-14올레핀), 이소아밀라우레이트, 세테아릴올리베이트, 소르비탄올리베이트, 마치현추출물, 글리세릴스테아레이트, 하이드록시아세토페논, 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머, 트로메타민, 캐모마일추출물, 국화꽃추출물, 디메치콘, 마테잎추출물, 상추추출물, 라벤더추출물, 패 추출물, 토코페릴아세테이트, 잔탄검, 소듐하이알루로네이트, 참마뿌리추출물, 하이드롤라이즈드옥수수전분, 베타-글루칸, 슈크로오스, 디소듐이디티에이 및 향료를 균일하게 배합하여 크림 타입의 화장품을 제조하였다.(C6-14 olefin), isoamyl laurate, cetearyl olivate, sorbitan olivate, sorbitan monooleate, sorbitan monooleate, sorbitan monooleate, glycerin, Lactic acid extract, Lactobacillus stearate, Lactobacillus stearate, Hydroxyacetophenone, Acrylate / C10-30 alkyl acrylate crosspolymer, Tromethamine, Chamomile extract, Chrysanthemum flower extract, Dimethicone, Extracts, tocopheryl acetate, xanthan gum, sodium hyaluronate, yam root extract, hydrolyzed corn starch, beta-glucan, sucrose, disodium dithiophosphate and fragrance are uniformly mixed to form a cream-type cosmetic .
(4) (4) 실시예Example 3 3
정제수, 글리세린, 하이드록시에칠우레아, 나이아신아마이드, 프로판디올, 스쿠알란, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 피이지/피피지-17/6코폴리머, 부틸렌글라이콜, 디메치콘, 페닐트리메치콘, 트리에칠헥사노인, 디메치콘/비닐디메치콘크로스폴리머, 첨차잎추출물, 카프릴릴글라이콜, 패 추출물, 토코페릴아세테이트, 소듐하이알루로네이트, 카프릴하이드록사믹애씨드, 해바라기씨오일, 아데노신, 비에이치티, 아가, 카라기난추출물, 콩오일, 소듐스타치옥테닐석시네이트, 말토덱스트린, 칼슘판토테네이트, 소듐아스코빌포스페이트, 피리독신에이치씨엘, 빅사씨오일, 토코페롤, 실리카, C12-14파레스-12, 디소듐이디티에이, 페녹시에탄올 및 클로페네신을 균일하게 배합하여 올인원 크림 타입의 화장품을 제조하였다.But are not limited to, water, purified water, glycerin, hydroxyethanol, niacinamide, propanediol, squalane, ammonium acryloyldimethyltaurate / vpicopolymer, Phenyltrimethicone, trimethicone, dimethicone / vinyl dimethicone crosspolymer, succulent tea leaf extract, caprylic glycol, Lahore extract, tocopheryl acetate, sodium hyaluronate, caprylhydroxamic acid, Sodium ascorbyl phosphate, pyridoxine HCI CI, Vicassian oil, tocopherol, silica, sodium bicarbonate, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sunflower seed oil, adenosine, Viechi tea, agar, carrageenan extract, soybean oil, sodium starch octenyl succinate, maltodextrin, calcium pantothenate, C12-14 pares-12, disodium iodide, phenoxyethanol and chlorphenesin were uniformly mixed to prepare an all-in-one cream type cosmetic.
(5) (5) 실시예Example 4 4
정제수, 에탄올, 부틸렌글라이콜, 나이아신아마이드, 1,2-헥산디올, 글리세레스-26, 마치현추출물, 하이드록시아세토페논, 피이지-40하이드로제네이티드캐스터오일, 옥틸도데세스-16, 패 추출물, 판테놀, 라벤더추출물, 상추추출물, 마테잎추출물, 하이드록시에칠셀룰로오스, 국화꽃추출물, 캐모마일추출물, 카보머, 트로메타민, 소듐하이알루로네이트, 디소듐이디티에이, 클로페네신 및 향료를 균일하게 배합하여 토너 타입의 화장품을 제조하였다.Extracts such as water, purified water, ethanol, butyleneglycol, niacinamide, 1,2-hexanediol, glycereth-26, hyaluronic acid extract, hydroxyacetophenone, phage-40 hydrogenated castor oil, octyldodeces- , Panthenol, Lavender Extract, Lettuce Extract, Mattee Extract, Hydroxyethylcellulose, Chrysanthemum Flower Extract, Chamomile Extract, Carbomer, Tromethamine, Sodium Hyaluronate, Disodium Iodide, Clofenacin and Spices Were uniformly mixed to prepare a toner-type cosmetic.
실험 조건Experimental conditions
(1) 세포 배양 및 패 추출물의 세포 독성 평가(1) Cytotoxicity of cell cultures and extracts
패 추출물의 수면유도 효과 검증을 위해 먼저 in vitro 세포 모델을 이용하여 세포 독성이 없는 농도를 세포 증식 억제 실험을 통해 결정하였다.In order to examine the effect of water extract on the sleep induction, we first determined the cytotoxicity - free concentration using an in vitro cell model.
이를 위해 C6 glioma 세포주를 RPMI 1640 배지(10% fetal bovine serum, 1% 페니실린-스트렙토마이신 포함)에서 배양하였으며, 패 추출물은 96 well plate에서 C6 glioma 세포를 24시간 동안 CO2 배양기에서 키운 후 IO 추출물을 농도별로 처리하였고, 추가배양 후 WST-1 cell proliferation kit(Cayman chemical, MI, USA)를 이용하여 흡광도를 측정하여 세포 독성을 검증하였다.For this purpose, C6 glioma cells were cultured in RPMI 1640 medium (10% fetal bovine serum, 1% penicillin-streptomycin), and C6 extracts were grown in CO 2 incubator for 24 hours in 96-well plates. . After further culturing, the cytotoxicity was verified by measuring the absorbance using WST-1 cell proliferation kit (Cayman chemical, MI, USA).
(2) 멜라토닌 수용체 발현 검증((2) Verification of melatonin receptor expression in vitroin vitro ))
멜라토닌 수용체 발현의 검증은 C6 glioma 세포에 패 추출물을 농도별로 처리 후 mRNA 수준에서의 멜라토닌 수용체의 발현을 검증하였다.The expression of melatonin receptors was examined in the mRNA level of C6 glioma cells after treatment with L - extracts.
이를 위해 24 well plate에 3×104개의 C6 glioma 세포를 넣어 키운 후 패 추출물을 농도별(0, 0.01, 0.05 mg/mL)로 처리하였다. 24시간 추가 배양한 후 trizol reagent(Ambion, NY, USA)를 사용하여 전체 RNA를 추출하였고, cDNA 합성 후 PCR법으로 멜라토닌 수용체 1과 2의 발현을 검증하였으며, housekeeping gene인 GAPDH 유전자의 발현을 internal control로 삼아 상대적인 발현을 검증하였다. PCR 반응은 94℃에서 4분 반응 후, 95℃ 20초, 60℃ 39초, 72℃ 5분 반응을 35 cycle로 진행하였다.For this purpose, 3 × 10 4 C6 glioma cells were cultured in a 24-well plate, and then treated with the cell extract (0, 0.01, 0.05 mg / mL). After incubation for 24 hrs, total RNA was extracted using trizol reagent (Ambion, NY, USA). The expression of
(3) 멜라토닌 검증을 위한 동물 실험((3) Animal experiments for melatonin validation in in vivovivo ))
패 추출물 처리에 의한 체내 수면유도 물질(melatonin)의 증감 여부를 확인하기 위해 수컷 마우스(C57BL6N, 6주령) 16마리를 구입하여 인천대학교 동물실험실에서(22~23℃, 상대습도 55~60%, 명암주기 12시간) 실험 실시 전 1주일간 사육환경에 적응시킨 후 체중을 측정하여 군당 평균체중이 비슷하도록 8마리씩 분리하여 패 추출물의 효과를 검증하였다.Sixteen male mice (C57BL6N, 6 weeks old) were purchased from an animal laboratory of Incheon University (22 ~ 23 ℃, relative humidity 55 ~ 60% After 12 weeks of light period, the mice were adapted to the breeding environment for 1 week before the experiment and the body weight was measured.
패 추출물은 1g/day/kg body weight 기준으로 1일 1회, 4주간 투여하였으며 오후 5시에 경구투여하였다. 대조군 마우스에는 같은 볼륨(250 uL)의 phosphate buffer saline(PBS)를 경구투여하였으며, 체중은 1주일 간격으로 측정하였다.The extracts were administered once a day for 4 weeks on a 1 g / day / kg body weight basis and then administered orally at 5 pm. Control mice were orally administered the same volume (250 uL) of phosphate buffer saline (PBS) and body weights were measured at weekly intervals.
모든 동물실험은 인천대학교 동물실험윤리위원회의 지침에 따라 수행하였다(INU-2016-07). All animal experiments were conducted according to the guidelines of the Animal Experimentation Ethics Committee of the University of Incheon (INU-2016-07).
(4) 멜라토닌 정량((4) Quantification of Melatonin in in vivovivo ))
패 추출물 처리에 따른 멜라토닌 함량 변화를 측정하기 위해 패 추출물을 4주간 급여한 마우스와 대조군 마우스에서 마지막 시료 급여 후 4시간 후에 심장채혈법으로 혈액을 채취하여 혈청을 분리한 후 50 mL 볼륨의 혈청을 멜라토닌 정량에 이용하였다.To determine the changes of melatonin content in the extracts, 4 hours after the last sample feeding, blood samples were collected by cardiac blood collection and the serum was separated. Melatonin was used for quantification.
멜라토닌은 mouse melatonin ELISA kit(MyBioSource Co., CA, USA)를 이용하여 측정하였다. Melatonin was measured using a mouse melatonin ELISA kit (MyBioSource Co., CA, USA).
(5) 마우스 brain 멜라토닌 수용체 발현량 검증((5) Verification of melatonin receptor expression level in mouse brain in in vivovivo ))
패 추출물 급여 후 마우스 뇌에서의 멜라토닌 수용체의 발현양상은 4주간의 패 추출물 급여 후 뇌조직을 적출하여 western blotting법으로 멜라토닌 수용체 MT1과 MT2의 발현양상을 검증하였다.The expression pattern of melatonin receptors in mouse brain after feeding of L - extract was examined by Western blotting of melanocortin receptors MT1 and MT2 after 4 weeks of feeding of L - extracts.
뇌조직을 cell lysis buffer(20 mM Tris-HCl, pH 7.4, 150 mL NaCl, 5 mM EDTA, 1%(w/v) IGEPAL CA-630, 5 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride)에 넣고 tissue homogenizer(Hanzhou Miu instruments Co., zhejing, China)로 조직을 분쇄하였으며, 원심분리 후 상층액을 분석에 사용하였다.The brain tissues were lysed in cell lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mL NaCl, 5 mM EDTA, 1% (w / v) IGEPAL CA-630, 5 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride) and the tissue was homogenized with a tissue homogenizer (Hanzhou Miu instruments Co., zhejing, China). The supernatant was centrifuged and the supernatant was used for the analysis.
마우스 멜라토닌 수용체 MT1과 MT2의 검증을 위해 rabbit anti-MT1 antibody와 rabbit anti-MT2-antibody(Origene, MD, USA)를 이용하였고, goat anti-rabbit IgG-HRP(Santacruz, CA, USA)를 2차 항체로 사용하였으며, 최종적으로는 ECL solution(Biorad, Seoul, Korea)을 이용하여 필름에 현상하였다. The rabbit anti-MT1 antibody and rabbit anti-MT2-antibody (Origene, MD, USA) were used for the detection of mouse melatonin receptors MT1 and MT2, and goat anti-rabbit IgG-HRP (Santacruz, Antibody was used and finally developed on film using ECL solution (Biorad, Seoul, Korea).
(6) 통계분석(6) Statistical analysis
실험 결과는 통계분석 프로그램(SAS 9.1)을 이용하여 분석하였고, student-t test법으로 검증하였으며, 결과치는 평균±표준편차(SD)로 나타내었다.Test results were analyzed using statistical analysis program (SAS 9.1) and verified by student-t test method. The results were expressed as mean ± SD.
실험 결과Experiment result
(1) 패 추출물의 세포 독성 평가(1) Evaluation of cytotoxicity of extracts
패 추출물의 세포 독성을 검증하기 위해 C6 glioma 세포주에 농도별 처리 후 세포의 생존율을 검증하였다.Cell viability of the C6 glioma cell line was examined after treatment at the concentration to examine the cytotoxicity of the extract.
도 1에서 보듯이, 패 추출물은 0.1 mg/mL 수준의 농도에서부터 세포의 생존율에 영향을 미치는 것으로 파악되었다.As shown in FIG. 1, the extracts of Lard influenced the survival rate of cells from the concentration of 0.1 mg / mL.
따라서, 본 실험에서는 패 추출물의 0.01과 0.05 mg/mL 수준의 첨가가 멜라토닌 수용체 MT1 및 MT2의 발현에 미치는 영향성을 검증하였다.Therefore, in this experiment, the effects of 0.01 and 0.05 mg / mL of L. extract on the expression of melatonin receptors MT1 and MT2 were examined.
(2) 패 추출물이 멜라토닌 수용체 발현에 미치는 (2) The effect of Lactobacillus extract on melatonin receptor expression 영향성Influence 평가 evaluation
패 추출물이 멜라토닌 수용체 발현에 미치는 영향을 평가하기 위해 패 추출물(0, 0.01, 0.05 mg/mL)을 C6 glioma 세포주에 처리 후 세포내 MT1과 MT2의 mRNA 수준에서의 발현을 RT-PCR로 검증하였다.In order to evaluate the effect of L-arabic extract on melatonin receptor expression, expression of mRNA levels of intracellular MT1 and MT2 in rat C6 glioma cell line was assayed by RT-PCR (0, 0.01, 0.05 mg / mL) .
도 2에서 보듯이, MT1 발현의 경우 패 추출물의 농도에 의존적으로 증가하는 현상을 볼 수 있다(P<0.05). MT2의 경우 0.01 mg/mL 수준의 패 추출물 처리시에는 미약하게 증가하는 현상을 보이나 통계적 유의성을 보이지 않았다(P>0.05).As shown in FIG. 2, the expression of MT1 increases depending on the concentration of Lactobacillus extract (P <0.05). MT2 showed a slight increase at the level of 0.01 mg / mL of L. extract but not statistically significant (P> 0.05).
이러한 결과는 패 추출물이 멜라토닌 수용체 중 MT1의 발현을 효과적으로 증가시킬 수 있는 효능을 보유하고 있다는 것을 증명해 주며, 이는 멜라토닌에 의한 세포내 신호전달이 더 강하게 증가되어 수면유도 현상을 촉진할 수 있다는 가능성을 시사하는 것이다.These results demonstrate that Lactobacillus extract possesses the ability to effectively increase the expression of MT1 in melatonin receptors, suggesting that melatonin-induced intracellular signaling may be more strongly promoted to promote sleep induction It is suggestive.
(3) 패 추출물이 멜라토닌 발현에 미치는 (3) The effect of Lactobacillus extract on melatonin expression 영향성Influence 평가( evaluation( in in vivovivo ))
패 추출물 처리에 의한 멜라토닌 함량 변화를 측정하기 위해 C57BL/6 마우스에(n=8) 4주간 패 추출물을 급여한 후 대조군 마우스(PBS 급여, n=8)의 혈중 멜라토닌 함량의 양과 비교하여 패 추출물의 멜라토닌 발현유도 효과를 검증하였다.To investigate the changes in melatonin content by the treatment with L-elaborate, C57BL / 6 mice (n = 8) were fed 4 h of L. extract and compared with the amount of melatonin in the blood of control mice (PBS, n = 8) Induced melatonin expression.
도 3에서 보듯이, 4주간에 1g/day/kg body weight 수준으로 급여한 패 추출물은 대조군과의 체중변화 비교에서 유의적인 차이를 보이지 않았다.As shown in FIG. 3, there was no significant difference in the weight change between the control group and the control group fed at 1 g / day / kg body weight level over 4 weeks.
이는 급여한 패 추출물의 농도 수준이 생체에 큰 독성으로 작용하지 않고 부작용이 없었음을 간접적으로 증명해 주는 것이다.This indirectly demonstrates that the concentration level of the saline roe extract does not act as a major toxic to the living body and has no side effects.
또한, 4주간의 패 추출물 급여 후 혈액을 추출하여 혈청속의 멜라토닌 함량을 측정하고, 대조군과 비교한 결과를 도 4에 나타내었다.In addition, the blood was extracted after 4 weeks of feeding of Lactobacillus extract, and the content of melatonin in the serum was measured, and the result of comparison with the control group is shown in FIG.
도 4에서 보듯이, 패 추출물의 4주간 급여는 혈중 멜라토닌 함량을 대조군 대비 약 12% 증가시킨 것으로 나타났다(대조군: 585.56±52.04 pg/mL, 처리군: 654.14±47.13 pg/mL, n=8, P<0.05).As shown in FIG. 4, the 4-week feeding of Lactobacillus extract increased the melatonin content of the blood by about 12% (control: 585.56 ± 52.04 pg / mL, treated group: 654.14 ± 47.13 pg / P < 0.05).
(4) 패 추출물 처리에 의한 마우스 brain 멜라토닌 수용체의 발현 변화 측정((4) Measurement of Melatonin Receptor Expression in Mouse Brain Treated with Lard Extract in vivoin vivo ))
패 추출물 급여에 따른 멜라토닌 수용체의 변화를 측정하기 위해 패 추출물을 4주간 1g/day/kg body weight 수준으로 급여한 후 마우스 뇌조직을 적출하여 뇌조직속의 MT1과 MT2의 발현량을 western blotting으로 검증하였다(n=4).To determine the changes of melatonin receptors according to the feeding of the extracts, the extracts were fed at a level of 1 g / day / kg body weight for 4 weeks. Mouse brain tissues were extracted and the expression levels of MT1 and MT2 in the granulosa were determined by western blotting (N = 4).
도 5에서 보듯이, 패 추출물 급여군에서는 MT1의 발현이 약 2.2배 이상 증가하였으나(p<0.05), MT2 발현의 경우는 유의적인 증가 현상을 보이지 않았다(p>0.05).As shown in FIG. 5, MT1 expression was increased by about 2.2-fold (p <0.05) in the Lactobacillus casei extract group but not significantly in the MT2 expression group (p> 0.05).
이러한 결과는 in vitro 세포수준에서 확인한 패 추출물이 멜라토닌 수용체 발현 현상에 미치는 결과(도 2)와 일치하는 것으로, 패 추출물이 실제로 체내에서 멜라토닌 수용체 발현을 증가시키는 효능을 보유하고 있다는 것을 증명하고 있으며, 멜라토닌 수용체의 발현유도를 통해 수면유도 현상을 증가시킬 수 있다는 사실을 한번 더 증명해 주는 것이다.These results are in agreement with the results (Fig. 2) of the melatonin receptor expression observed at the in vitro cell level, demonstrating that the Lactobacillus extract actually has the effect of increasing melatonin receptor expression in the body, It is once again demonstrated that induction of melatonin receptor expression can increase sleep induction.
(5) 수면유도 기능성 화장품의 인체적용시험 결과(5) Human body application test result of sleep inducing functional cosmetics
(주)KC피부임상연구센터에 의뢰하여 실시예 1 내지 4에 따라 제조된 수면유도 기능성 화장품 4종의 피부 톤, 피부 결, 보습력 개선 및 수면도움 효과를 평가하였으며, 그 결과는 하기 표 2와 같다.Skin texture, moisturizing power and sleep aid effect of four kinds of water-induced functional cosmetics manufactured according to Examples 1 to 4 were evaluated by the KC Skin Clinical Research Center Co., Ltd. The results are shown in Table 2 same.
[표 2][Table 2]
결과 검토Review results
본 발명은 패 추출물이 수면유도 효과에 중요한 분자지표인 멜라토닌 수용체 및 멜라토닌의 발현유도에 효과적임을 입증하였다.The present invention proves that Lepidoptera extract is effective in inducing expression of melatonin receptors and melatonin which are molecular indicators important for the water-induced induction effect.
패 추출물의 수면유도 효과를 검증하기 위해 세포수준(in vitro) 및 동물(in vivo) 실험을 통해서 멜라토닌 및 멜라토닌 수용체 유도 효과를 검증하였다.Melatonin and melatonin receptor - inducing effects were verified by in vitro and in vivo experiments in order to verify the sleep - inducing effect of extracts.
기존에 수면유도 효능이 있는 것으로 알려진 소재들은 대부분 멜라토닌의 발현을 유도할 수 있는지 여부를 검증하여 소재의 수면유도 효과 보유 여부를 증명하는데 그치고 있지만, 본 발명에 사용된 패 추출물은 멜라토닌 발현을 유도할 뿐만 아니라 멜라토닌 수용체의 발현까지 유도하는 기능을 보유하는 것으로 확인되었다.Although most of the materials known to have sleep inducing effects have proved whether or not they can induce the expression of melatonin, they have proved whether or not the material has a sleep inducing effect. However, the L-extract used in the present invention induces melatonin expression But also to induce the expression of melatonin receptors.
멜라토닌 수용체는 멜라토닌에 의한 수면유도 신호를 세포안으로 증폭하여 전달하는 역할을 함을 고려할 때, 멜라토닌 수용체의 증가는 똑같은 양의 멜라토닌 존재시 그 실제적인 수면유도 효과를 몇 배 더 증가시킬 것으로 판단된다.Considering that the melatonin receptor plays a role in amplifying and delivering the signal induced by melatonin to the cells, the increase of the melatonin receptor seems to increase the actual sleep inducing effect several times in the presence of the same amount of melatonin.
멜라토닌 및 멜라토닌 수용체는 불면증 및 신경불안증 등의 질병 치료에 효과적인 타겟으로 인식되어 있다. 따라서 본 발명에 따른 패 추출물은 향후 불면증 및 신경불안증 등의 질병 치료에 효과적인 소재 및 신약으로 발전할 가능성이 충분하다.Melatonin and melatonin receptors have been recognized as effective targets for the treatment of diseases such as insomnia and anxiety. Therefore, the L-extract according to the present invention is likely to develop into a material and a new drug effective for the treatment of diseases such as insomnia and anxiety.
사회의 발전으로 전 세계적으로 노인인구의 증가 현상이 뚜렷이 나타나고 있어 노인성 질환을 치유 및 억제할 수 있는 소재 내지 제품 개발에 대한 수요는 기하급수적으로 증가할 것이라 예상된다.With the development of society, the increase of the elderly population is evident all over the world, and the demand for material and product development that can heal and inhibit geriatric diseases is expected to increase exponentially.
특히, 노인성 질환의 대표적인 예인 불면증과 신경불안 증세를 나타내는 인구가 증가하는 현 시점에서, 본 발명은 수면유도 기능이 있는 화장품 및 식품 등의 새로운 소재로 활용되어 큰 파급 효과를 불러올 것으로 기대된다.In particular, at present, as a representative example of geriatric diseases, the population showing insomnia and nervous anxiety symptoms is increasing, the present invention is expected to be used as a new material for cosmetics and foods having a sleep inducing function, thereby causing a large ripple effect.
Claims (10)
수면유도 기능성 조성물.
Ishige okamurae ) extract as an active ingredient,
A sleep-inducing functional composition.
상기 패 추출물은 멜라토닌(melatonin)의 발현을 증가시키는 것임을 특징으로 하는,
수면유도 기능성 조성물.
The method according to claim 1,
Characterized in that said Lard extract promotes the expression of melatonin.
A sleep-inducing functional composition.
상기 패 추출물은 멜라토닌 수용체(MT1)의 발현을 증가시키는 것임을 특징으로 하는,
수면유도 기능성 조성물.
The method according to claim 1,
Lt; RTI ID = 0.0 > (MT1) < / RTI >
A sleep-inducing functional composition.
수면유도 기능성 화장료 조성물.
Ishige okamurae ) extract as an active ingredient,
A water-induced functional cosmetic composition.
상기 화장료 조성물은 에센스 타입이며,
정제수, 사이클로펜타실록산, 부틸렌글라이콜, 글리세린, 바이오사카라이드검-1, 디메치콘, 마치현추출물, 1,2-헥산디올, 피이지-10디메치콘/비닐디메치콘크로스폴리머, 폴리소르베이트20, 하이드록시아세토페논, 디메치콘/비닐디메치콘크로스폴리머, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 트로메타민, 카보머, 패 추출물, 토코페릴아세테이트, 알란토인, 소듐하이알루로네이트, 디메치콘올, 디소듐이디티에이 및 향료를 포함하는 것을 특징으로 하는,
수면유도 기능성 화장료 조성물.
5. The method of claim 4,
The cosmetic composition is an essence type,
1, dimethicone, horseradish extract, 1,2-hexanediol, phage-10 dimethicone / vinyl dimethicone crosspolymer, polysorbate 20, cyclodextrin, , Hydroxyacetophenone, dimethicone / vinyl dimethicone crosspolymer, ammonium acryloyldimethyltaurate / vpicopolymer, tromethamine, carbomer, tallow extract, tocopheryl acetate, allantoin, sodium hyaluronate, di Methicone, disodium edetate, and flavoring. ≪ RTI ID = 0.0 >
A water-induced functional cosmetic composition.
상기 화장료 조성물은 크림 타입이며,
정제수, 세틸에칠헥사노에이트, 글리세린, 부틸렌글라이콜, 1,2-헥산디올, 하이드로제네이티드폴리(C6-14올레핀), 이소아밀라우레이트, 세테아릴올리베이트, 소르비탄올리베이트, 마치현추출물, 글리세릴스테아레이트, 하이드록시아세토페논, 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머, 트로메타민, 캐모마일추출물, 국화꽃추출물, 디메치콘, 마테잎추출물, 상추추출물, 라벤더추출물, 패 추출물, 토코페릴아세테이트, 잔탄검, 소듐하이알루로네이트, 참마뿌리추출물, 하이드롤라이즈드옥수수전분, 베타-글루칸, 슈크로오스, 디소듐이디티에이 및 향료를 포함하는 것을 특징으로 하는,
수면유도 기능성 화장료 조성물.
5. The method of claim 4,
The cosmetic composition is a cream type,
(C6-14 olefin), isoamyl laurate, cetearyl olivate, sorbitan olivate, sorbitan monooleate, sorbitan monooleate, sorbitan monooleate, glycerin, Lactic acid extract, Lactobacillus stearate, Lactobacillus stearate, Hydroxyacetophenone, Acrylate / C10-30 alkyl acrylate crosspolymer, Tromethamine, Chamomile extract, Chrysanthemum flower extract, Dimethicone, Characterized in that it comprises an extract, tocopheryl acetate, xanthan gum, sodium hyaluronate, yam root extract, hydrolyzed corn starch, beta-glucan, sucrose,
A water-induced functional cosmetic composition.
상기 화장료 조성물은 올인원 크림 타입이며,
정제수, 글리세린, 하이드록시에칠우레아, 나이아신아마이드, 프로판디올, 스쿠알란, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 피이지/피피지-17/6코폴리머, 부틸렌글라이콜, 디메치콘, 페닐트리메치콘, 트리에칠헥사노인, 디메치콘/비닐디메치콘크로스폴리머, 첨차잎추출물, 카프릴릴글라이콜, 패 추출물, 토코페릴아세테이트, 소듐하이알루로네이트, 카프릴하이드록사믹애씨드, 해바라기씨오일, 아데노신, 비에이치티, 아가, 카라기난추출물, 콩오일, 소듐스타치옥테닐석시네이트, 말토덱스트린, 칼슘판토테네이트, 소듐아스코빌포스페이트, 피리독신에이치씨엘, 빅사씨오일, 토코페롤, 실리카, C12-14파레스-12, 디소듐이디티에이, 페녹시에탄올 및 클로페네신을 포함하는 것을 특징으로 하는,
수면유도 기능성 화장료 조성물.
5. The method of claim 4,
The cosmetic composition is an all-in-one cream type,
But are not limited to, water, purified water, glycerin, hydroxyethanol, niacinamide, propanediol, squalane, ammonium acryloyldimethyltaurate / vpicopolymer, Phenyltrimethicone, trimethicone, dimethicone / vinyl dimethicone crosspolymer, succulent tea leaf extract, caprylic glycol, Lahore extract, tocopheryl acetate, sodium hyaluronate, caprylhydroxamic acid, Sodium ascorbyl phosphate, pyridoxine HCI CI, Vicassian oil, tocopherol, silica, sodium bicarbonate, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sunflower seed oil, adenosine, Viechi tea, agar, carrageenan extract, soybean oil, sodium starch octenyl succinate, maltodextrin, calcium pantothenate, C12-14 pares-12, disodium iodide, phenoxyethanol and chlorphenesin.
A water-induced functional cosmetic composition.
상기 화장료 조성물은 토너 타입이며,
정제수, 에탄올, 부틸렌글라이콜, 나이아신아마이드, 1,2-헥산디올, 글리세레스-26, 마치현추출물, 하이드록시아세토페논, 피이지-40하이드로제네이티드캐스터오일, 옥틸도데세스-16, 패 추출물, 판테놀, 라벤더추출물, 상추추출물, 마테잎추출물, 하이드록시에칠셀룰로오스, 국화꽃추출물, 캐모마일추출물, 카보머, 트로메타민, 소듐하이알루로네이트, 디소듐이디티에이, 클로페네신 및 향료를 포함하는 것을 특징으로 하는,
수면유도 기능성 화장료 조성물.
5. The method of claim 4,
The cosmetic composition is a toner type,
Extracts such as water, purified water, ethanol, butyleneglycol, niacinamide, 1,2-hexanediol, glycereth-26, hyaluronic acid extract, hydroxyacetophenone, phage-40 hydrogenated castor oil, octyldodeces- , Panthenol, Lavender Extract, Lettuce Extract, Mattee Extract, Hydroxyethylcellulose, Chrysanthemum Flower Extract, Chamomile Extract, Carbomer, Tromethamine, Sodium Hyaluronate, Disodium Iodide, Clofenacin and Spices ≪ / RTI >
A water-induced functional cosmetic composition.
수면유도 기능성 식품 조성물.
Ishige okamurae ) extract as an active ingredient,
A sleep-inducing functional food composition.
수면유도 기능성 약제학적 조성물.
Ishige okamurae ) extract as an active ingredient,
A sleep-inducing functional pharmaceutical composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160180951A KR101908549B1 (en) | 2016-12-28 | 2016-12-28 | Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160180951A KR101908549B1 (en) | 2016-12-28 | 2016-12-28 | Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180076607A true KR20180076607A (en) | 2018-07-06 |
KR101908549B1 KR101908549B1 (en) | 2018-10-16 |
Family
ID=62921465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160180951A KR101908549B1 (en) | 2016-12-28 | 2016-12-28 | Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101908549B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110229755A (en) * | 2019-06-17 | 2019-09-13 | 昆明理工大学 | A method of promote bloom nitrogen stress to coerce lower microalgae grease using epiphysin and accumulates |
KR102097632B1 (en) * | 2019-12-30 | 2020-04-06 | 정은우 | Cosmetic composition |
KR20210096932A (en) * | 2020-01-29 | 2021-08-06 | 코스바이오 주식회사 | Composition for preventing, improving or treating sleep disorders comprising Artemisia capillaris extract |
KR102483531B1 (en) * | 2022-06-17 | 2023-01-04 | 한국콜마주식회사 | cosmetic composition with ductility |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100039104A (en) * | 2008-10-07 | 2010-04-15 | 부경대학교 산학협력단 | An anti-oxidant active composition containing compounds from ishige okamurae |
KR100981184B1 (en) | 2007-12-27 | 2010-09-10 | 부경대학교 산학협력단 | solation of antioxidant compound from Ishige okamurae and its manufacturing process |
KR20120091995A (en) * | 2011-01-03 | 2012-08-20 | 한국식품연구원 | Composition for invigorating GABAA-benzodiazepine receptor and composition having anxiolitic anti-convulsant anti-depressant and sleep-improving effect containing Brown Seaweed extract |
KR20150039643A (en) * | 2013-10-02 | 2015-04-13 | 한국식품연구원 | Purification method of Phlorotannins from brown algae |
-
2016
- 2016-12-28 KR KR1020160180951A patent/KR101908549B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100981184B1 (en) | 2007-12-27 | 2010-09-10 | 부경대학교 산학협력단 | solation of antioxidant compound from Ishige okamurae and its manufacturing process |
KR20100039104A (en) * | 2008-10-07 | 2010-04-15 | 부경대학교 산학협력단 | An anti-oxidant active composition containing compounds from ishige okamurae |
KR20120091995A (en) * | 2011-01-03 | 2012-08-20 | 한국식품연구원 | Composition for invigorating GABAA-benzodiazepine receptor and composition having anxiolitic anti-convulsant anti-depressant and sleep-improving effect containing Brown Seaweed extract |
KR20130020701A (en) * | 2011-01-03 | 2013-02-27 | 한국식품연구원 | Composition for invigorating gabaa-benzodiazepine receptor and composition having anxiolitic, anti-convulsant, anti-depressant and sleep-improving effect containing brown seaweed extract |
KR20150039643A (en) * | 2013-10-02 | 2015-04-13 | 한국식품연구원 | Purification method of Phlorotannins from brown algae |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110229755A (en) * | 2019-06-17 | 2019-09-13 | 昆明理工大学 | A method of promote bloom nitrogen stress to coerce lower microalgae grease using epiphysin and accumulates |
KR102097632B1 (en) * | 2019-12-30 | 2020-04-06 | 정은우 | Cosmetic composition |
KR20210096932A (en) * | 2020-01-29 | 2021-08-06 | 코스바이오 주식회사 | Composition for preventing, improving or treating sleep disorders comprising Artemisia capillaris extract |
KR102483531B1 (en) * | 2022-06-17 | 2023-01-04 | 한국콜마주식회사 | cosmetic composition with ductility |
Also Published As
Publication number | Publication date |
---|---|
KR101908549B1 (en) | 2018-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2672871T3 (en) | Fermentation product of the embryonic soy axis containing equol and method of obtaining it | |
KR101908549B1 (en) | Cosmetic composition comprising ishige okamurae extract with sleeping induction function, and cosmetics using the same | |
ES2523853T3 (en) | Use of a Wolfberry extract to maintain and / or restore skin tone and / or firmness | |
TW200843726A (en) | Agent for relief or prevention of xerostomia | |
TW200423961A (en) | Composition for promoting production of type I collagen and/or elastin | |
JP6482930B2 (en) | Skin cosmetics and foods and drinks | |
JP2010540623A (en) | Soybean fermented polymer substance mixed with folic acid and composition containing the same | |
JP7379152B2 (en) | Composition for inhibiting muscle fibrosis | |
JP2009107965A (en) | Ceramide synthesis promoter, and external preparation for skin and food and drink | |
AU2019233471B2 (en) | Composition for improving skin conditions | |
CN106852725A (en) | Composition for improving skin | |
JP2023075284A (en) | oral composition | |
CN107106479A (en) | Improve the composition of the cellulite outward appearance of skin | |
CN106659752A (en) | Composition containing scutellaria alpina extract | |
JP7281801B2 (en) | Epidermal stem cell differentiation promoter | |
KR20180044772A (en) | Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof | |
CN103182004B (en) | Containing tealeaves, camellia and tea seed extract, for preventing or improving the composition of metabolic syndrome | |
KR20130010192A (en) | Composition for promoting leptin secretion comprising specific compounds as effective component | |
KR102090133B1 (en) | Composition comprising Hibiscus syriacus L. extract for caring damages of skin cells by microdust | |
JP5465037B2 (en) | Anti-aging agent, antioxidant, whitening agent, immunostimulant, external preparation for skin and functional oral composition | |
JP2020186215A (en) | Composition for improvement of menopause symptom | |
JP2019202967A (en) | Anti-aging composition, anti-aging skin cosmetics and anti-aging food and drink | |
JP7421184B2 (en) | Agents for increasing and/or maintaining skin moisture content and skin oil content | |
KR102073759B1 (en) | Composition comprising NADH for preventing or treating metabolic disease | |
JP2019034902A (en) | Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |